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Abstract
Background: The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD 
requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of 
cardiovascular medicines in developing countries using the standardized data collected according to the World Health 
Organization/Health Action International methodology.
Methods: The following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. 
Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international 
reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one 
month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only 
for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and 
summarized by World Bank Income Groups.
Results: For all measures, there was great variability across surveys. The overall availability of cardiovascular medicines 
was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some 
countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than 
international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive 
medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment 
became unaffordable.
Conclusions: The results of this study emphasize the need of focusing attention and financing on making chronic 
disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal.
Background
The global burden of cardiovascular diseases (CVD) is on
the rise and at present 30% of all deaths worldwide are
due to cardiovascular conditions [1]. The great majority
(80%) of these deaths now occur in developing countries
[2]. Recent projections on the global burden of disease
predict that mortality rates of cardiovascular diseases will
continue to increase and CVD will rank as leading cause
of death in all parts of the world by 2030 [3]. The epide-
miological transition describes how changes in lifestyle
and healthcare system lead to an increasing percentage of
deaths due to chronic cardiovascular conditions [4]. In
order to successfully treat these conditions and reach to
the next stage of the epidemiological transition in which
deaths are prevented and the onset of disease is delayed,
adequate treatment and prevention programs need to be
implemented. Within this treatment strategy, ongoing
pharmaceutical management with combination therapy
using multiple medicines is of great importance. Recur-
rences of CVD can be diminished by 75% when adequate
combination therapy is used [5].
The WHO-PREMISE study investigating the secondary
prevention of CVD in ten low- and middle income coun-
tries found that pharmaceutical use was often insuffi-
cient. Among the patients with coronary heart disease,
18.8% did not receive aspirin, 51.9% did not receive a
beta-blocker, 60.2% did not receive an angiotensin-con-
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verting enzyme (ACE) inhibitor and 79.2% did not receive
a statin [6]. Whether this lack of pharmaceutical treat-
ment was due to non-compliance or limited access to
medicines was not investigated in this study, however
these results call for further research.
In the past, a number of studies on medicine availability
and prices have been undertaken, some of which focused
specifically on cardiovascular medicines. A Mexican
study found that hydrochlorothiazide was the only treat-
ment option that did not become less affordable between
1990 and 1996; 1.1% of the minimum wage was needed to
pay for chronic treatment. Other CVD medicines
increased up to threefold in price and treatment cost as
m u c h  a s  4 7 %  o f  t h e  m i n i m u m  w a g e  [ 7 ] .  A  s t u d y  p e r -
formed in Ghana found that 93% of patients did not com-
ply with their antihypertensive treatment regimen, 96% of
which reported high medicine prices as the reason for not
complying [8]. Other studies investigating medicine pric-
ing in general, including cardiovascular medicines, found
that medicines were generally poorly available and highly
priced [9-12].
Many of the investigations, however, did not use a stan-
dardized methodology, which makes it difficult to com-
pare results across studies. In order to facilitate more
standardized research into medicine prices, Health
Action International (HAI) and the World Health Orga-
nization (WHO) have developed a standardized survey
methodology to investigate medicine prices, availability,
affordability and price components in the supply chain.
Previous analyses of WHO/HAI data for medicines used
to treat chronic conditions such as hypertension, asthma
and diabetes showed that medicines were poorly avail-
able, in particular in public sector facilities. Prices of
medicines varied greatly across countries and the public
sector was usually less expensive than the private sector,
as were generics compared to originator brand products.
Many treatment options were not affordable, especially
when treatment with multiple medicines was necessary
[13,14]. Another analysis of the data for a basket of medi-
cines across 36 countries, which corrected for inflation
and purchasing power, showed very similar results [15].
The aim of this study is to perform a secondary analysis
of the availability, price and affordability of chronic-care
cardiovascular medicines in developing countries using
the WHO/HAI data, and correcting for inflation and pur-
chasing power. The medicines studied are atenolol, cap-
topril, hydrochlorothiazide, losartan and nifedipine, all of
which can be used to treat hypertension.
Methods
WHO/HAI data collection
The WHO/HAI methodology aims to generate reliable
information concerning the availability, price and afford-
ability of medicines and is briefly summarized here. All
surveys analysed in this research used the methodology
described in the first edition of the manual [16].
In each survey, data on availability and patient prices
are collected in a sample of outlets in the public and pri-
vate sector. Public sector procurement prices are also col-
lected, usually at a central level such as the Ministry of
Health or the Central Medical Store. In each survey, one
major urban centre and three randomly-chosen adminis-
trative regions within one day's travel of the urban area
are selected as survey areas. In each survey area, the main
public hospital and at least four other public medicine
outlets are selected to obtain data on public sector patient
prices. The private sector sample is chosen by selecting
the private outlet closest to each sampled public sector
outlet. Thus, a minimum of 20 outlets per survey per sec-
tor are sampled. In 2008, a second edition with slightly
different methodology was published [17].
Surveys are performed according to a standardized
protocol with results double-entered into a uniform
workbook for data analysis. In each survey, data are col-
lected on 30 (global) core medicines and up to 20 supple-
mentary medicines of local or regional importance. For
each medicine a fixed dosage form and strength is used.
Surveys are usually performed on a national level, but
large countries such as India and China have been sur-
veyed on a sub-national basis.
Outcome measures
Availability is expressed as the percentage of facilities
where the medicine is found on the day of data collection.
Only formulations of the same strength and dosage form
are included.
Price is expressed as a price per unit (e.g. tablet, dose)
and converted to a median price ration (MPR) by dividing
the median local price by an international reference price
(IRP). The IRP is obtained from the Management Sci-
ences for Health International Drug Price Indicator
Guide which reports median prices of high quality multi-
source medicines offered to developing and middle-
income countries by different suppliers [18]. Each survey
uses the IRP for the year prior to the survey and the IRP is
converted to local currency using the exchange rate on
the first day of data collection. Price ratios are not calcu-
lated when the medicine was present in less than four
outlets. In addition, treatment affordability is estimated
by calculating the number of day's wages the lowest-paid
unskilled government worker needs to purchase one
month's supply of medicines according to a standard
treatment regimen.
Secondary data analysis
The following anti-hypertensive medicines have been
included: captopril 25 mg, atenolol 50 mg, hydrochloro-
thiazide 25 mg, nifedipine retard 20 mg and losartan 50van Mourik et al. BMC Cardiovascular Disorders 2010, 10:25
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mg, all in either tablet or capsule form. Out of 19 anti-
hypertensive medicines in the database, these medicines
were chosen because they are the most-surveyed repre-
sentatives of five major pharmaceutical classes. Price
information was not analysed for losartan because there
was no reliable IRP available; losartan is not widely pro-
duced as a generic formulation because it is still under
patent in many countries [19]. At the time of the study, 45
surveys from 36 countries were available for analysis
(Table 1). The most recent data were extracted from the
WHO/HAI database which is available online [20].
In order to compare prices across different countries
and regions, several data adjustments have been made.
All prices have been converted back to the year 2004, as
the majority of surveys were conducted in this year.
Prices were standardized to IRPs for 2003 and to a com-
mon US dollar exchange rate as published by the Interna-
tional Monetary Fund [21]. For Uzbekistan the exchange
rate published by the United Nations Economic Commis-
sion for Europe was used; due to the multiple exchange
rates for Syria the exchange rate used in the surveys was
left unchanged.
To correct for either inflation or deflation that may
have occurred between the survey year and the base year
(2004), prices were adjusted using the consumer price
index (CPI) [21]. The consumer price index is a stan-
dardised measure of inflation which is calculated by com-
paring the price of a standardized basket of goods in the
current year to a baseline year. Adjusting prices to repre-
sent the survey year 2004 (thus using 2003 IRPs and cor-
recting prices using the CPI) allowed for evaluation of
public procurement prices across surveys and compari-
son of procurement prices with public sector patient
prices within surveys.
In order to compare patient prices across countries
and/or regions, prices were also adjusted for purchasing
power parity (PPP) [21]. PPP quantifies how much of a
basket of goods a specific quantity of US dollars will buy
in a specific country. Procurement prices were not cor-
rected for PPP because the pharmaceutical procurement
market is international and competitive and the price a
country pays generally does not depend on the purchas-
ing power of its inhabitants.
Brand premiums were calculated by dividing the
adjusted MPR for an originator product by the adjusted
MPR for its lowest-priced generic equivalent.
Data have been analysed by 2007 World Bank Income
Groups (Table 1) [22]. Results are reported as averages for
each income group.
Finally, in El-Salvador, India, Kuwait, Malaysia,
Morocco, Pakistan, Tunisia, Uganda and the United Arab
Emirates medicines were provided free-of-charge in the
public sector and as such no pricing data was analyzed for
the public sector in these countries.
Results
Availability
Availability of cardiovascular medicines varied consider-
ably across the surveyed countries, even within income
groups. Availabilities ranging from 0 to 100% within one
income group were no exception (tables 2 and 3).
Overall, atenolol 50 mg had the highest availability for
the lowest-priced generic (LPG) in both the public and
private sectors (38.9% and 73.3% respectively) and losar-
tan the lowest. The entire basket of cardiovascular medi-
cines had an average availability of 26.3% for the LPG in
the public sector and 57.3% in the private sector (LPG).
For all medicines, the private sector had better availability
than the public sector, both for LPGs and originator
brand products (OB).
In nearly all surveys, LPGs had a higher availability
than originator brand products. The only exception to
this was losartan, which is still under patent; ten out of
thirty surveys had better availability of the OB. Across
income groups, in both the public and private sector,
higher income regions tended to have better availability
than lower income regions. In the private sector, higher
income areas with a low availability of LPGs had a high
availability of OBs.
Public sector procurement prices
A comparison of public sector procurement prices
showed that they varied greatly both across medicines
and countries/regions. For example, the CPI-adjusted
MPR for captopril was 0.21 in Peru and the United Arab
Emirates and 12.75 in Morocco. This means that prices
Table 1: Countries surveyed classified by World Bank 
income group
Income group Countries surveyed
Low income (LI) Chad, Ethiopia, Ghana, India (Chennai, 
Haryana, Karnataka, Maharashtra 12 
districts, Maharashtra 4 regions, 
Rajasthan, West-Bengal), Kenya, 
Kyrgyzstan, Mali, Mongolia, Nigeria, 
Pakistan, Sudan (Gadarif, Khartoum, 
Kordofan), Tajikistan, Tanzania, Uganda, 
Uzbekistan, Yemen.
Lower-middle 
income (LMI)
Armenia, Cameroon, China (Shandong, 
Shanghai), El-Salvador, Fiji, Indonesia, 
Jordan, Morocco, Peru, Philippines, Sri 
Lanka, Syria, Tunisia.
Upper-middle 
income (UMI)
Brazil (Rio de Janeiro), Kazakhstan, 
Lebanon, Malaysia, South Africa (Kwazulu 
Natal State)
High income (HI) Kuwait, United Arab Emirates
Abbreviations: LI - Low income; LMI - Lower middle income; UMI 
- Upper middle income; HI - High income.van Mourik et al. BMC Cardiovascular Disorders 2010, 10:25
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ranged from 0.21 to 12.75 times the international refer-
ence price. The average procurement MPR for both
generic and originator products are summarized in Fig-
ure 1. It is important to realize that MPR is a measure rel-
ative to the international reference price, not an absolute
measure. This may explain the high MPR for hydrochlo-
rothiazide. There was no data available concerning the
procurement of originator brand hydrochlorothiazide.
No particular relationship could be found across World
Bank Income Groups. Nigeria and Mongolia had the
highest procurement prices for several medicines. Some
countries were capable of obtaining consistently low pro-
curement prices, in particular Ethiopia, Fiji and Jordan.
Data matched by medicine, which allow for comparison
of procurement prices and public sector patient prices
within one survey, were only available for a very limited
number of surveys and medicines (data not shown). It
could be seen that in Ethiopia and Tanzania patient prices
were at least 50% more expensive than the procurement
price for three out of four medicines. On the other hand,
patient prices were lower than procurement prices for
several medicines in Nigeria.
Table 2: Public sector percentage availability by World Bank income group (weighted averages).
Atenolol Captopril HCT Losartan Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB LPG OB
%%%%%%%%%%%%
( n )( n )( n )( n )( n )( n )( n )( n )( n )( n )
LI 40.7
(20)
0.8
(20)
18.6
(21)
1.4
(21)
15.0
(21)
0.4
(16)
2.2
(16)
0.0
(13)
24.5
(19)
0.2
(19)
20.8 0.6
LMI 17.8
(8)
3.8
(8)
59.4
(9)
8.7
(9)
51.3
(9)
0.0
(9)
8.6
(8)
12.1
(8)
20.4
(8)
21.5
(8)
32.6 9.0
UMI 5.0
(3)
3.3
(3)
5.0
(3)
66.7
(3)
33.3
(2)
0.0
(2)
0.0
(3)
30.0
(3)
35.0
(3)
0.0
(3)
14.4 21.4
HI 93.0
(2)
10.5
(2)
81.3
(2)
5.6
(2)
46.9
(2)
0.0
(1)
0.0
(1)
72.2
(1)
50.0
(2)
100.
0
(2)
60.3 38.1
All 38.9
(33)
2.3
(33)
31.5
(35)
9.1
(35)
27.7
(34)
0.2
(28)
3.7
(28)
10.4
(25)
26.0
(32)
11.7
(32)
26.3 6.8
Abbreviations: HCT - hydrochlorothiazide; LPG - lowest priced generic; OB - originator brand; LI - Low income; LMI - Lower middle income; 
UMI - Upper middle income; HI - High income.
Table 3: Private sector percentage availability by World Bank income group (weighted averages).
Atenolol Captopril HCT Losartan Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB LPG OB
%%%%%%%%%%%%
( n )( n )( n )( n )( n )( n )( n )( n )( n )( n )
LI 79.7
(22)
32.5
(22)
25.9
(23)
24.0
(23)
35.5
(22)
1.7
(18)
46.0
(16)
5.7
(13)
74.8
(21)
13.0
(21)
52.3 17.0
LMI 59.1
(10)
38.9
(10)
83.5
(11)
39.4
(11)
64.3
(10)
8.9
(10)
37.8
(10)
42.9
(10)
45.6
(9)
38.6
(9)
58.8 33.9
UMI 72.3
(4)
66.8
(4)
68.5
(4)
84.4
(4)
55.5
(3)
21.7
(3)
15.0
(3)
66.7
(3)
82.1
(3)
36.9
(3)
60.1 57.7
HI 76.0
(2)
98.0
(2)
16.7
(2)
94.0
(2)
50.0
(2)
0.0
(1)
0.0
(1)
100
(1)
34.8
(2)
98.0
(2)
39.4 85.0
All 73.3
(38)
42.8
(38)
59.4
(40)
36.5
(40)
45.9
(37)
6.7
(32)
38.6
(30)
29.8
(27)
65.6
(35)
26.5
(35)
57.3 29.2
Abbreviations: HCT - hydrochlorothiazide; LPG - lowest priced generic; OB - originator brand; LI - Low income; LMI - Lower middle income; 
UMI - Upper middle income; HI - High income.van Mourik et al. BMC Cardiovascular Disorders 2010, 10:25
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Patient prices
Figure 2 summarizes the average median price ratios for
the LPG and the OB in the public and private sector. Data
classified by income group is presented in tables 4 and 5.
Across the cardiovascular medicines, captopril (LPG)
had the lowest MPR in both the public and private sector.
The highest MPR was found for hydrochlorothiazide.
When comparing the public and private sector, it can be
seen that for LPGs, the private sector was on average
more expensive for all medicines. Importantly, countries
that provide medicines for free in the public sector were
not included to calculate the average MPR. For originator
brand products, a direct comparison between the public
and private sector could not be made due to the very lim-
ited availability of OB products in the public sector.
Lower income countries (LI and LMI) tended to have
higher adjusted prices than the upper income countries
(UMI and HI), both in the public and private sector.
Again, some countries had consistently high or low prices
across multiple medicines. High prices were found in El-
Salvador and the Philippines, while low prices were often
found in Fiji and Yemen.
Brand premiums
Brand premiums were calculated when possible; there
was insufficient data available to calculate brand premi-
ums in the public sector due to the low availability of OB
products. Results are presented in figure 3. It was found
that on average, brand premiums were lower in higher
i n c o m e  c o u n t r i e s  a s  c o m p a r e d  t o  l o w e r  i n c o m e  a r e a s.
Countries with high brand premiums for multiple medi-
cines were Fiji and Peru, while low brand premiums could
often be found in El-Salvador, Kuwait and the UAE.
Affordability
Data for affordability were limited, in particular in the
public sector; for losartan and nifedipine data were only
available from two and three surveys, respectively. There-
fore, the results may not always be representative of the
entire sample.
In the public sector (n = 28, from 18 countries/regions),
it cost on average 2.0 (LPG) and 8.3 (OB) day's wages to
purchase one month of treatment with one of the cardio-
vascular medicines. On average affordability was better in
the private sector (1.8 and 5.3 day's wages for the LPG
and OB). When countries were matched, however, the
private sector was usually less affordable than the public
sector. Atenolol was most affordable, with an average of
1.1 day's wages for the LPG. When matched across sur-
veys, the LPG was in all cases more affordable than the
OB product, both in the public and private sector. Over-
all, cardiovascular medicines were least affordable in the
low income regions. Upper-middle income countries
scored particularly well, especially when compared to
high income regions.
Discussion
Findings
Overall availability of the five cardiovascular medicines
was low, with an average availability of 57.3% in the pri-
Figure 1 Procurement MPRs (CPI adjusted) for the LPG and the OB. The line represents a price ratio equal to 1.0 (procurement at the same price 
as the international reference price). Abbreviations: HCT - hydrochlorothiazide; LPG - lowest-priced generic; OB - originator brand; MPR - Median Price 
Ratio.
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vate sector and 26.3% in the public sector. However, avail-
abilities of over 80% were observed in some countries
(public and/or private sector). Availability of the lowest-
priced generics was higher than originator brand prod-
ucts in most surveys and private sector availability was
higher than public sector availability in all surveys. How-
ever, even in the private sector availability was not uni-
versal and prices were nearly always higher. In general,
higher income countries had higher medicine availability
than lower income countries, both in the public and pri-
vate sector. Differences in the presence of CVD medi-
cines on National Essential medicines lists, where they
exist, may explain the (poor) availability of medicines in
some countries. For example, in some countries enalapril
was chosen as an essential ACE-inhibitor rather than
captopril which was surveyed [23].
Average public sector procurement prices were rela-
tively high; in the past, a MPR equal to or below 1.0 has
been described as a reasonable procurement price [13].
Some countries achieved procurement prices well below
the international reference price for a number of medi-
cines, whereas others consistently paid higher prices [24].
As would be expected, generics were procured at lower
prices than originator products. When comparing public
sector procurement and patient prices, it was seen that in
some cases patients were charged less than the procure-
ment price. This could reflect that countries are aware of
the high prices for essential chronic disease medicines
Table 4: Public sector patient MPR (CPI and PPP adjusted), by World Bank income group (weighted averages).
Atenolol Captopril HCT Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB
(n) (n) (n) (n) (n) (n) (n) (n)
LI 15.7
(7)
7.2
(7)
15.8
(1)
40.5
(4)
9.8
(6)
15.9 15.8
LMI 40.2
(3)
122.3
(1)
6.9
(6)
71.2
(2)
12.0
(4)
9.5
(2)
20.4
(1)
15.3 71.3
UMI 7.0
(1)
15.2
(1)
9.5
(1)
12.4 7.0
HI
All 23.0
(10)
122.3
(1)
7.0
(13)
41.3
(4)
25.0
(9)
9.7
(9)
20.4
(1)
15.5 51.3
Blank cases are due to missing data. Abbreviations: LPG - lowest priced generic; OB - originator brand; HCT - hydrochlorothiazide; LI - low 
income; LMI - lower-middle income; UMI - upper middle income; HI - high income.
Table 5: Private sector patient MPR (CPI and PPP adjusted), by World Bank income group (weighted averages).
Atenolol Captopril HCT Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB
(n) (n) (n) (n) (n) (n) (n) (n)
LI 21.0
(22)
107.3
(13)
12.4
(21)
3.9
(9)
85.2
(16)
73.0
(1)
11.8
(20)
51.6
(7)
35.6 74.9
LMI 41.5
(9)
87.6
(7)
14.7
(12)
39.8
(10)
66.6
(10)
27.8
(6)
81.8
(6)
45.7 70.0
UMI 13.2
(3)
83.4
(3)
8.9
(3)
31.6
(4)
36.0
(3)
156.8
(3)
11.1
(3)
46.0
(2)
22.4 81.6
HI 26.8
(2)
37.2
(2)
10.7
(2)
12.1
(2)
55.2
(1)
13.9
(1)
23.6
(2)
38.5 31.3
All 25.8
(36)
93.2
(25)
12.7
(38)
34.1
(25)
73.0
(30)
135.8
(4)
15.0
(30)
58.3
(17)
30.2 65.4
Blank cases are due to missing data. Abbreviations: LPG - lowest priced generic; OB - originator brand; HCT - hydrochlorothiazide; LI - low 
income; LMI - lower-middle income; UMI - upper middle income; HI - high income.van Mourik et al. BMC Cardiovascular Disorders 2010, 10:25
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and are using a cross-subsidizing system to lower these
prices. In other cases however, patient prices in the public
sector were much higher than procurement prices, which
could be due to high mark-ups and taxes along the supply
chain.
As with availability, patient prices varied greatly among
surveys. In countries in which patients paid for medicines
in the public sector, the average cost of LPGs was less
than in the private sector for all medicines. However , a
lack of availability in the public sector may force patients
to purchase their medicines in the more highly priced
private sector or forgo treatment altogether. For example,
captopril had an adjusted MPR of 0.67 in the public sec-
tor in Jordan but only 61% availability. In the private sec-
tor, captopril had a much higher availability (90%), but
the patient would need to pay 19.02 times the IRP.
As would be expected, generics were priced lower than
originator brand products in nearly all surveys for all
medicines. Our calculations of brand premiums show
that to purchase an originator brand medicine costs 4.2
times as much as buying the lowest-priced generic. Inter-
estingly, brand premiums were on average lower in
upper-middle and high income countries. One would
hope this smaller price differential was due to lower
prices for the originator brand, but unfortunately this was
due to higher prices being charged for generic products.
This can occur when price regulations set the price for
the generics discounted from the price charged for origi-
nator brand products, as occurs in Kuwait [13].
Overall, patient prices for cardiovascular medicines
were high compared to international reference prices. For
LPGs, the average adjusted MPR for the entire group of
medicines was 15.5 in the public sector and 30.2 in the
private sector.
The affordability data showed that on average one
month of chronic treatment with one medicine for hyper-
tension cost 1.8 day's wages. In all cases, originator brand
products and the private sector were less affordable. Skip-
ping one or two meals was often not enough to purchase
treatment and often more than one day's wages were
needed to purchase one month of treatment; therefore
cardiovascular medicines may be labelled as unaffordable
in a significant proportion of countries. Furthermore, an
important part of the patient population requires combi-
nation therapy with multiple anti-hypertensives to reach
treatment goals, amounting to an unaffordable treatment
package. Finally, in one-income families, chronic treat-
ment becomes particularly unaffordable if more than one
family member has a medical condition that requires
treatment.
Figure 2 Average CPI and PPP adjusted MPRs for atenolol, captopril, hydrochlorothiazide and nifedipine. Abbreviations: HCT - hydrochloro-
thiazide; LPG - lowest priced generic; OB - originator brand; MPR - Median Price Ratio.
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Strengths and weaknesses
T h e  s t r e n g t h  o f  t h i s  r e s e a r c h  l i e s  i n  t h e  s t a n d a r d i z e d
WHO/HAI methodology which has been validated
through pilot and validation studies and adapted accord-
ingly [17].
However, some difficulties do exist. Outcome mea-
s u r es,  i n  pa rt i cu l a r  a va i l a b i l i t y ,  m a y  be  a ff ect ed  b y  t h e
exclusion of alternate dosage forms and strengths or ther-
apeutic alternatives. Also, availability data do not reflect
average availability over time since availability data is only
collected on one specific day. Furthermore, median price
ratios may be skewed when international reference prices
are based on limited data [18]. For this reason, price data
for losartan were not analysed. It is important to realize
that the MPR is a relative measure of price and does not
provide information on the absolute price of a medicine;
thus the absolute price of hydrochlorothiazide may be
lower than that of nifedipine even though the latter has a
lower MPR.
In some cases, data in one or more income group may
have been skewed due to the small number of surveys in
that category or dominance of one country within one
income group. The latter occurred a number of times
with surveys from India, which due to the unique nature
of the Indian pharmaceutical market and the large num-
ber of Indian surveys, may have influenced outcomes in
the low income group.
Calculating affordability based on the wage of the gov-
ernment worker may lead to an over-optimistic result
since a significant proportion of the population earns less
than this amount [14]. Alternative measures for afford-
ability are currently under investigation [25]. A further
problem for the affordability analysis was that only a lim-
ited number of surveys calculated affordability of these
medicines.
Implications
Based on the outcomes of this analysis, several implica-
tions for policy making can be emphasized. The poor
availability in the public sector limits patient access to
medical treatment by forcing them to resort to the more
highly priced private sector, which has better, although
not optimal, availability. The public sector is often seen as
a last resort, but as our data show, the private sector fails
to meet the needs of those least able to afford highly
priced products. Improving public sector availability can
be achieved by implementing more efficient procurement
in the countries that pay high procurement prices,
improving distribution systems and providing adequate
and sustainable financing. Furthermore, focusing (lim-
ited) resources on a selected group of generic essential
chronic disease medicines instead of aiming to supply a
broad range of generic and originator brand medicines
may lead to better availability of priority treatments [15].
In some countries, lowering procurement prices could
help bring patient prices down [26]. Strategies to improve
procurement efficiency include competitive procurement
with price transparency, national pooled purchasing and
purchasing by generic name [17]. Differential pricing
based on the wealth of countries could also lower prices.
This differential pricing already occurs for originator
b r a n d  p r o d u c t s  t o  s o m e  d e g r e e ,  b u t  n o t  a s  m u c h  f o r
generic products [27]. Promoting differential pricing
could benefit lower income countries, not only affecting
medicine prices, but also improving the availability of
medicines. Options and strategies for differential pricing
are currently being explored and promoted [28,29].
Addressing excessive mark-ups between procurement
and patient prices could help bring prices down. For
example in Syria, the maximum percentage mark-up
allowed is determined based on the cost of the medicine;
more expensive medicines are allotted a relatively lower
mark-up to prevent preferential selling of highly priced
products [15,30]. Furthermore, exempting medicines
from tariffs and taxes, such as the value-added tax, will
lower prices and prevent taxing of the sick [14,26]. It
must then be ensured that savings obtained are passed on
to patients. Furthermore, it has been found that in some
countries, particularly in Sudan and China, revenue from
medicine sales in the public sector is used to finance
other parts of the public health care system [15,31,32].
Because the public sector is primarily used by the poor,
this practice is inequitable and alternative sources of
financing should be sought [15].
Furthermore, continuous support for the use of generic
products can contribute to keeping the costs of medicines
down, both in the public and private sector. Several strat-
egies have been proposed, including ensuring product
quality, encouraging or requiring generic substitution,
preferential registration procedures and education of
health care professionals and consumers [14].
Although generic medicines were usually priced lower
and were more available than originator products in the
private sector, some were still relatively overpriced as can
be seen by the small brand premiums in high income
countries [13]. In some cases, this could be prevented by
implementing policies that do not regulate generic prices
based on the price charged for brand products.
No matter how inexpensive medicines are in the private
sector, the poorest sections of population in developing
countries will still not be able to afford them. F urther ,
chronic disease treatment requires lifelong therapy in
order to prevent potentially life-threatening complica-
tions. Such demand is predictable and creates a responsi-
bility on the health care system to ensure continued
availability. Health insurance which covers out-patient
chronic disease medicines is therefore of key importance.
In this line of reasoning, investing in expensive facilitiesvan Mourik et al. BMC Cardiovascular Disorders 2010, 10:25
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such as stroke or cardiac care units should only occur
when reliable access to hypertensive medicines has been
achieved.
Conclusions
This analysis reveals that many problems remain with the
availability, prices and affordability of cardiovascular
medicines. To improve the situation, medicine policies
should be adapted to promote the use of generic medi-
cines, promote sustainable and reliable methods of pro-
curement and financing and prevent excessive mark-ups
in the supply chain. Also, continuing research into medi-
cine pricing is necessary, as medicine prices continue to
evolve and policy changes continue to have effects.
Implementing medicine price monitoring programmes
and performing price component analyses should be con-
ducted to gain more insight into medicine prices and
allow for adaptation of policies to specific countries.
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